Skip to content

Effects of Oxycodone Combined with Dexmedetomidine on Weaning Success and Delirium in Elderly Patients with Severe Pneumonia Undergoing Mechanical Ventilation

Effects of Oxycodone Combined with Dexmedetomidine on Weaning Success and Delirium in Elderly Patients with Severe Pneumonia Undergoing Mechanical Ventilation

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500108469
Enrollment
Unknown
Registered
2025-09-01
Start date
2025-09-01
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe pneumonia

Interventions

Experimental group (Oxycodone and Dexmedetomidine combination group):Oxycodone hydrochloride injection 30 mg (10 mg/vial) was diluted with 0.9% NaCl solution to a total volume of 50 ml and administere
Control group (Remifentanil and Dexmedetomidine combination group):Remifentanil injection 4 mg (1 mg/vial) was diluted with 0.9% NaCl solution to a total volume of 50 ml and administered by continuous

Sponsors

The 242nd Hospital Affiliated to Shenyang Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Age >= 65 years; 2. Subjects meeting the diagnostic criteria for severe pneumonia as defined by the American IDSA/ATS guidelines, requiring endotracheal intubation and mechanical ventilation; 3. Expected mechanical ventilation duration >= 24 hours, with enrollment within 48 hours of initiation of ventilation; 4. Subjects requiring ICU monitoring; 5. Subjects who agree to participate in the study and have signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. History of allergy to study medications; 2. Conditions requiring deep sedation; 3. Severe hepatic or renal dysfunction; 4. Uncorrected hypovolemic shock; 5. Severe systemic diseases; 6. Severe psychiatric disorders or cognitive impairment; 7. History of delirium; 8. Prior or recent use of sedatives, analgesics, or other medications affecting sedation assessment; 9. History of substance abuse and/or alcoholism.

Design outcomes

Primary

MeasureTime frame
Incidence of delirium within 72 hours (assessed by CAM-ICU);

Secondary

MeasureTime frame
CPOT scores and RASS scores ;Incidence of agitation;Weaning success rate;Hemodynamic changes; the occurrence of adverse reactions during treatment, including nausea, vomiting, respiratory depression, hypertension, hypotension, bradycardia, tachycardia, and other related events.;

Countries

China

Contacts

Public ContactHongwei Gao

The 242nd Hospital Affiliated to Shenyang Medical College

dongyu8210@126.com+86 158 4007 6685

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026